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Abstract
Background: Percutaneous coronary intervention (PCI) is a necessary procedure commonly performed for patients
with coronary artery disease (CAD). However, the impact of diabetes and hypertension on long-term outcomes of
patients after receiving PCI has not yet been determined.
Methods: The data of 1234 patients who received PCI were collected prospectively, and patients were divided into
four groups, including patients with and without DM and those with either DM or hypertension alone. Baseline
characteristics, risk factors, medications and angiographic findings were compared and determinants of
cardiovascular outcomes were analyzed in patients who received PCI.
Results: Patients with DM alone had the highest all-cause mortality (P < 0.001), cardiovascular mortality and
myocardial infarctions (MI) (both P < 0.01) compared to the other groups. However, no differences were found
between groups in repeat PCI (P = 0.32). Cox proportional hazard model revealed that age, chronic kidney disease
(CKD), previous MI and stroke history were risk factors for all-cause mortality (OR: 1.05,1.89, 2.87, and 4.12,
respectively), and use of beta-blockers (BB) and statins reduced all-cause mortality (OR: 0.47 and 0.35, respectively).
Previous MI and stroke history, P2Y12 inhibitor use, and syntax scores all predicted CV mortality (OR: 4.02, 1.89, 2.87,
and 1.04, respectively). Use of angiotensin converting enzyme inhibitors (ACEI), beta-blockers (BB), and statins
appeared to reduce risk of CV death (OR: 0.37, 0.33, and 0.32, respectively). Previous MI and syntax scores predicted
MI (OR: 3.17 and 1.03, respectively), and statin use reduced risk of MI (OR: 0.43). Smoking and BB use were
associated with repeat PCI (OR: 1.48 and 1.56, respectively).
Conclusions: After PCI, patients with DM alone have higher mortality compared to patients without DM and
hypertension, with both DM and hypertension, and with hypertension alone. Comorbid hypertension does not
appear to increase risk in DM patients, whereas comorbid DM appears to increase risk in hypertensive patients.
Trial registration: REC103-15 IRB of Taichung Tzu-chi Hospital
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Background
Percutaneous coronary intervention (PCI) refers to coron-
ary revascularization through a trans-arterial approach
using a various spectrum of devices. PCI is necessary and
commonly performed for patients with coronary artery dis-
ease (CAD). Clinical outcomes of patients with PCI may
include myocardial infarction (MI), revascularization and
mortality [1]. Major risk factors such as diabetes mellitus
(DM), hypertension, dyslipidemia and smoking can also
affect outcomes in CAD patients receiving PCI.
The impact of DM and hypertension on outcomes in
patients with acute coronary syndrome (ACS) receiving
PCI has been well studied. Hypertension did not affect
short-and long term mortality in patients with ST eleva-
tion myocardial infarction (STEMI) receiving PCI [2, 3].
However, hypertension was the only independent long-
term predictor of mortality in patients with unstable
angina (US) receiving coronary stenting [4]. Insulin-
treated diabetes mellitus (ITDM) was a strong predictor
for long-term mortality when compared with non-DM
or non-ITDM patients [5]. After receiving PCI, diabetic
patients with ACS had worse short- and mid-term out-
comes than non-diabetes patients with ACS [6–9]. For
ACS patients with both DM and hypertension, the
combination of DM and hypertension appeared to be
strongly associated with mortality than in patients with
DM or hypertension alone [10]. For patients with stable
CAD after receiving PCI, diabetes was still an adverse
predictor for mid-term outcomes [11, 12].
However, the combined effect of diabetes and hyper-
tension on long-term outcomes in patients receiving PCI
remains obscure. For this reason, the aim of the present
study was to clarify and compare the long-term out-
comes in four groups of patients: those with diabetes
and hypertension, those with only DM, those with only
hypertension, and those without either DM or hyperten-
sion. We also further analyzed the predictors for adverse
clinical outcomes among these four groups.
Methods
Study population
This prospective cohort study was conducted via medical
record survey from 2007 through 2014. We recruited con-
secutive PCI patients aged 20 to 90 years from the in-
patient clinic at Taichung Tzu Chi Hospital, Taiwan. The
patients were divided into four groups: patients without
DM and hypertension, patients with DM alone, patients
with hypertension alone, and patients with both DM and
hypertension. Patients with scheduled PCI and malignancy
were excluded. Most patients were followed regularly via
the outpatient department (OPD). For the few patients
lost to follow-up at the OPD, a telephone call was usually
used to contact the patients themselves or their families.
For each patient, a survey on cardiovascular mortality (CV
mortality), all-cause mortality, MI and repeated PCI
procedures was completed at the end of the study. The
Institutional Review Board and ethics committee
approved the study protocol and signed informed consent
was obtained from all study participants.
Data collection, measurements and analysis
Data of body habitus, baseline biochemical data,
hemodynamic data on cardiac catheterization, exposed
risk factors and differences between treatment strategies
such as drug medications or invasive procedures
(balloon angioplasty, bare metal stent deployment or
drug-eluting stent deployment) were all collected for
analysis. The measurements of body parameters in-
cluded body height, body weight, and body mass index
(BMI). The following baseline biochemical data were
collected: fasting plasma glucose, creatinine, total choles-
terol, high density lipoprotein-cholesterol (HDL-C), low
density lipoprotein-cholesterol (LDL-C) and serum tri-
glyceride level. For hemodynamic data, we collected cen-
tral aortic pressure (CAP) and left ventricular ejection
fraction (LVEF). CAP was measured via pigtail catheter
while performing coronary angiography. Angiographic
findings, including number of diseased vessels and lesion
locations were recorded, and lesion severity and com-
plexity were evaluated by Synergy between Percutaneous
Coronary Intervention with Taxus and Cardiac Surgery
score (Syntax Score) [13]. The left ventricular ejection
fraction was estimated via angiographic ventriculography
or scintigraphic ventriculography. Diabetes was defined
as a fasting plasma glucose level of more than 126 mg/
dL, a causal plasma glucose level greater than 200 mg/dl
or hemoglobin A1c (HbA1c) level of more than 6.5%
[14]. Hypercholesterolemia was defined as a serum chol-
esterol level of more than 200 mg/dL or an LDL-C level
of more than 100 mg/dL. Chronic kidney disease (CKD)
was defined as an estimated glomerular filtration rate
(eGFR) of less than 60 ml/min/1.73 m2, which is equal
to or more than stage III chronic kidney disease (CKD)
[15]. Previous MI history was defined as a history of MI
prior to index PCI, accompanied by a threefold elevation
of cardiac enzymes from the baseline value. Related clin-
ical parameters, including baseline characteristics,
hemodynamic data, major risk factors, angiographic
findings and invasive strategies, were compared between
the four groups. Clinical outcomes, including cardiovas-
cular mortality, all-cause mortality, de novo MI, and
repeated PCI were also analyzed in the four groups. Risk
factors for adverse clinical outcomes were analyzed to
compare differences between the four groups.
Statistical analysis
Statistical analysis was used primarily to compare differ-
ences between the four groups. Analysis of variance
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(ANOVA) was used to evaluate continuous variables,
whereas chi-squared test or Fisher’s exact test were used
to evaluate categorical variables. The log-rank test and
Kaplan-Meier curves were used for survival analysis.
The Cox proportional hazards model was used to
eveluate effects of the independent variables on hazards.
P values of less than 0.05 were considered statistically
significant. All analyses were performed using the
statistical package SPSS for Windows (Version 22.0 SPSS
Inc., Chicago, IL, USA).
Results
During the study period, a total of 1234 patients who
received the PCI procedure were enrolled. Of these, 359
patients in the control group had neither DM nor hyper-
tension, 178 patients had DM alone, 382 patients had
hypertension alone, 315 patients had both DM and
hypertension. No differences were found in mean
follow-up time between the four groups (control group:
173.8 ± 106.8 weeks, DM alone: 155.4 ± 104.8 weeks,
Hypertension alone: 168.8 ± 99.7 weeks, both DM and
hypertension: 160.9 ± 99.0 weeks, P = 0.170).
Patients’ baseline clinical characteristics are listed in
Table 1. No significant age differences were found
among the four groups (P = 0.11). For body habitus pa-
rameters, patients with hypertension alone and patients
with both DM and hypertension had higher BMI values
compared with the other two groups (P < 0.01). For
hemodynamic parameters, patients with both DM and
hypertension had the highest central systolic pressure
(CSP) compared with the other groups (P < 0.01),
whereas patients with hypertension alone had the high-
est central diastolic pressure (CDP) compared with the
other groups (P < 0.01). For baseline biochemistries,
patients with DM alone had the lowest cholesterol and
HDL-C levels (P = 0.03 and P < 0.01, respectively), while
patients with both DM and hypertension had the
poorest renal function (P < 0.01).
The demographic data of the study population are
presented in Table 2. Patients with DM and hyperten-
sion included more females and more CKD cases (both
P < 0.01). Hypercholesterolemia was more likely in
patients with hypertension alone, whereas b patients
without DM and hypertension were most likely to be
current smokers (both P < 0.01). Having a previous
history of MI was highest in patients with DM alone
(P < 0.01). Patients with DM and hypertension had the
highest use of diuretics, beta blockers (BB) and
angiotension receptor blockers (ARB) (all P < 0.01).
Patients with hypertension alone used calcium
channel blockers (CCB) and statins more frequently
(both P < 0.01), but patients with DM alone had
higher use of ace inhibitors (ACEI) (P < 0.01). Results
of angiographic findings and clinical outcomes are
shown in Table 3. Among angiographic findings, dual
and triple vessel disease were found more frequently
in patients with both DM and hypertension (P < 0.01),
and these patients also had a larger number of
treated vessels and lesions (both P < 0.01). No differ-
ences were found in invasive strategies among the
four groups (P = 0.81). Among patient outcomes,
patients with DM alone had the highest all-cause mortality
and cardiovascular mortality rates (both P < 0.01); how-
ever, no differences were found in MI and repeated PCI
rate between the four groups (P = 0.09 and P = 0.32, re-
spectively). Figure 1 shows the cumulative rate of freedom
Table 1 General characteristics of the study population









Age (years) 62.1 ± 12.7 62.3 ± 10.8 63.9 ± 11.5 64.4 ± 10.7 0.10
Weight (kg) 66.3 ± 11.7 67.5 ± 13.2 68.5 ± 13.0 68.6 ± 13.8 0.08
Height (cm) 163.1 ± 7.9 161.8 ± 8.7 162.1 ± 8.6 161.9 ± 8.8 0.18
BMI (kg/m2) 24.8 ± 3.5 25.7 ± 4.1 26.0 ± 4.0 26.0 ± 4.0 <0.01
CSP 126.9 ± 20.8 130.0 ± 20.0 141.9 ± 21.6 145.7 ± 25.6 <0.01
CDP 71.8 ± 12.2 70.5 ± 12.4 76.1 ± 13.0 72.8 ± 13.6 <0.01
Cholesterol (mg/dl) 182.7 ± 44.2 171.3 ± 42.2 182.1 ± 42.0 179.1 ± 49.0 0.03
HDL (mg/dl) 41.5 ± 15.8 36.8 ± 14.4 40.2 ± 16.4 37.1 ± 15.4 <0.01
TG (mg/dl) 149.9 ± 110.9 153.8 ± 102.0 155.1 ± 95.1 177.3 ± 121.6 <0.01
LDL (mg/dl) 111.3 ± 39.7 103.8 ± 34.7 110.9 ± 38.2 106.2 ± 39.7 0.07
Serum creatinine (mg/dl) 1.3 ± 1.3 1.8 ± 2.2 1.6 ± 1.9 2.3 ± 2.9 <0.01
Uric acid (mg/dl) 6.6 ± 2.0 6.6 ± 2.2 6.5 ± 2.1 7.2 ± 2.0 0.06
DM alone diabetes alone, HT alone hypertension alone, DM and HT both DM and hypertension, BMI body mass index, Central SP central aortic systolic pressure,
Central DP central aortic diastolic pressure, HDL high-density lipoprotein cholesetrol, LDL low- density lipoprotein cholesterol, TG triglyceride
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from MI, cardiovascular death, all-cause death and
repeated PCI among the four groups. Freedom from all-
cause death and CV death were lowest in the DM alone
group (both P < 0.01); however, no differences were
found in MI and repeated PCI rate between the four
groups (P = 0.06 and P = 0.10, respectively).
Outcomes analysis and significant predictors of out-
come evaluated by Cox proportion hazard model for MI,
all-cause death, CV-death, and repeated PCI are shown
in Table 4. Patients with DM alone carried the highest
risk compared with the control group in terms of MI,
CV death, all-cause death, and repeated PCI (Odds
Ratio: 2.15, 2.25, 1.90, and 1.70, respectively, P < 0.01).
Results of the Cox proportional hazard model revealed
that previous MI and Syntax scores were predictors for
MI (OR: 3.17 and 1.03, respectively), and use of statins
reduced the risk of MI (OR: 0.43). Age, CKD, previous
MI and stroke history were predictors for all-cause death
(OR: 1.05, 1.89, 2.87, and 4.12, respectively), and use of
BB and statins reduced the risk (OR: 0.47 and 0.35,
respectively). Previous MI and stroke history, use of
P2Y12 inhibitors, and syntax scores were all predictors
of CV death (OR: 4.02, 1.89, 2.87, and 1.04, respectively),
use of BB, ACEI, and statins reduced the risk of CV
death (OR: 0.37, 0.33, and 0.32, respectively). Finally,
smoking and use of BB were associated with repeated
PCI procedures (OR: 1.48 and 1.56, respectively).
Discussion
In the present study, patients with coronary artery
disease receiving percutaneous coronary intervention
had the highest rate of all-cause mortality and CV mor-
tality compared to patients without DM and hyperten-
sion, patients with both DM and hypertension, and
those with hypertension alone and DM alone. However,
no difference were found in de novo MI and repeated
Table 2 Demography of study population and medications
used after first time PCI










F 61 (17.0%) 44 (24.7%) 110 (28.8%) 110 (34.9%)
M 298 (83.0%) 134 (75.3%) 272 (71.2%) 205 (65.1%)
CKD <0.01
No 318 (88.6%) 132 (74.2%) 304 (79.6%) 196 (62.2%)
Yes 41 (11.4%) 46 (25.8%) 78 (20.4%) 119 (37.8%)
Hypercholesterolemia <0.01
No 145 (40.4%) 98 (55.1%) 145 (38.0%) 156 (49.5%)
Yes 214 (59.6%) 80 (44.9%) 237 (62.0%) 159 (50.5%)
Current smoker <0.01
No 192 (53.5%) 132 (74.2%) 241 (63%) 224 (71.1%)
Yes 167 (46.5%) 46 (25.8%) 141 (37.0%) 91 (28.9%)
Previous MI <0.01
No 209 (58.2%) 98 (55.1%) 278 (72.7%) 222 (70.5%)
Yes 150 (41.8%) 80 (44.9%) 104 (27.2%) 93 (29.5%)
Stroke history 0.09
No 347 (96.7%) 164 (92.1%) 357 (93.5%) 293 (93.0%)
Yes 12 (3.3%) 14 (7.9%) 25 (6.5%) 22 (7.0%)
CABG history 0.67
No 358 (99.7%) 176 (98.9%) 380 (99.5%) 313 (99.4%)
Yes 1 (0.3%) 2 (1.1%) 2 (0.5%) 2 (0.6%)
Asprin 0.25
No 24 (6.7%) 21 (11.8%) 34 (8.9%) 26 (8.3%)
Yes 335 (93.3%) 157 (88.2%) 348 (91.1%) 289 (91.8%)
P2Y12 inhibitors 0.66
No 65 (18.1%) 35 (19.7%) 64 (16.8%) 49 (15.6%)
Yes 294 (81.9%) 143 (80.3%) 318 (83.3%) 266 (84.4%)
Diuretics 0.01
No 296 (82.5%) 131 (73.6%) 300 (78.5%) 229 (72.7%)
Yes 63 (17.6%) 47 (26.4%) 82 (21.5%) 86 (27.3%)
BB 0.10
No 213 (59.3%) 107 (60.1%) 213 (55.8%) 160 (50.8%)
Yes 146 (40.7%) 71 (39.9%) 169 (44.2%) 155 (49.2%)
CCB <0.01
No 294 (81.9%) 126 (70.8%) 223 (58.4%) 197 (62.5%)
Yes 65 (18.1%) 52 (29.2%) 159 (41.6%) 118 (37.5%)
ACEI <0.01
No 255 (71.0%) 127 (71.4%) 310 (81.2%) 254 (80.6%)
Yes 104 (29.0%) 51 (28.7%) 72 (18.9%) 61 (19.4%)
Table 2 Demography of study population and medications
used after first time PCI (Continued)
ARB <0.01
No 316 (88.0%) 159 (89.3%) 267 (69.9%) 211 (67.0%)
Yes 43 (12.0%) 19 (10.7%) 115 (30.1%) 104 (33.0%)
Statin <0.01
No 232 (64.6%) 134 (75.3%) 214 (56.0%) 210 (66.7%)
Yes 127 (35.4%) 44 (24.7%) 168 (44.0%) 105 (33.3%)
Fibrate 0.08
No 337 (93.9%) 170 (95.5%) 355 (92.9%) 283 (89.8%)
Yes 22 (6.1%) 8 (4.5%) 27 (7.1%) 32 (10.2%)
DM alone diabetes alone, HT alone hypertension alone, DM and HT both DM
and hypertension, Previous MI history of previous myocardial infarction, CABG
history history of coronary artery bypass graft, CKD chronic kidney disease,
P2Y12 inhibitor P2Y12 receptor inhibitor of platelet, BB beta-blockers, CCB
calcium channel blocker, ACEI angiotensin-converting enzyme inhibitor, ARB
angiotensin receptor blocker
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PCI between the four groups. Age, CKD, previous MI
and stroke history were predictors for all-cause death.
Previous MI and stroke history, use of P2Y12 inhibitors,
and syntax scores were all predictors for CV death.
Previous MI history and syntax scores were predictors
for MI, and smoking and use of BB were associated with
repeated PCI procedures. While statin use reduced the
risk of MI, CV death and all-cause death, BB reduced
the risk of CV death and all-cause death, and CEI
reduced CV death.
Results of the present study also showed that patients
with DM alone as well as patients with both DM and
hypertension had a higher prevalence of elevated serum
creatinine levels and CKD, and for this reason, the use
of diuretics was also higher than in the other groups. On
the other hand, for renal function, patients with DM and
hypertension had more elevated serum creatinine levels
and increased prevalence of CKD than patients with DM
alone (P < 0.04 and P < 0.007, respectively).
Given that hypertension seems to have an adverse
effect on renal function in DM patients, hypotensive
agents with more potency such as ARB were used more
frequently than ACEI for BP control in patients with
DM and hypertension (33% vs. 19.4%, P < 0.001). In con-
trast, compared with patients with DM alone, or patients
with both DM and hypertension, ACEI were used more
Table 3 Demography of angiographic findings and outcome









Follow-up time (weeks) 173.8 ± 106.8 155.4 ± 104.8 168.8 ± 99.7 160.9 ± 99.0 0.17
Number of diseased vessels <0.01*
Single vessel disease 206 (57.4%) 74 (41.6%) 186 (48.7%) 124 (39.4%)
Dual vessel disease 93 (25.9%) 55 (30.9%) 107 (28.0%) 100 (31.8%)
Triple vessel disease 60 (16.7%) 49 (27.5%) 89 (23.3%) 91 (28.8%)
Mean of treated vessels 1.6 ± 0.8 1.9 ± 0.8 1.7 ± 0.8 1.9 ± 0.8 <0.01*
Mean of treated lesions 1.3 ± 0.7 1.4 ± 0.8 1.5 ± 0.8 1.6 ± 0.9 <0.01*
Type of intervention 0.81
Balloon angioplasty 122 (30.0%) 62 (15.2%) 125 (30.7%) 98 (24.1%)
BMS deployment 144 (28.7%) 60 (11.8%) 171 (33.7%) 131 (25.8%)
DES deployment 116 (25.8%) 68 (15.1%) 137 (30.4%) 129 (28.7%)
Lesion location 0.62
LAD 249 (69.2%) 138 (78.0%) 288 (75.4%) 183 (58.1%)
Lcx 163 (45.2%) 96 (54.2%) 183 (48.0%) 191 (60.6%)
RCA 162 (45.0%) 99 (55.9%) 199 (52.0%) 175 (55.6%)
SYNTAX score 10.8 ± 8.0 11.9 ± 7.9 10.1 ± 6.9 11.6 ± 8.5 <0.01*
LVEF 0.60 ± 0.13 0.55 ± 0.16 0.62 ± 0.13 0.59 ± 0.15 0.71
MI 0.09
yes 15 (4.2%) 14 (7.9%) 12 (3.1%) 17 (5.4%)
no 344 (95.8%) 164 (92.1%) 370 (96.9%) 298 (94.6%)
CV death <0.01*
yes 20 (5.6%) 24 (13.5%) 13 (3.4%) 17 (5.4%)
no 339 (94.4%) 154 (86.5%) 369 (96.6%) 298 (94.6%)
All-cause death <0.01*
yes 35 (9.8%) 36 (20.2%) 21 (5.5%) 22 (7.0%)
No 324 (90.3%) 142 (79.8%) 361 (94.5%) 293 (93.0%)
Re-PCI 0.32
yes 84 (23.4%) 51 (28.7%) 82 (21.5%) 73 (23.2%)
No 275 (76.6%) 127 (71.4%) 300 (78.5%) 242 (76.8%)
BMS bare metal stent, DES drug-eluting stent, LAD left anterior descending artery, Lcx left circumflex artery, RCA right coronary artery, SYNTAX score Synergy
between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score, LVEF left ventricular ejection fraction, MI myocardial infarction, Re-PCI repeated
percutaneous coronary intervention. *: significant
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often than in the other two groups because of the higher
prevalence of previous MI. In the present study, patients
with DM alone had the lowest rate of hypercholesterol-
emia, and statin use was the lowest in this group com-
pared to the other groups. Although statin use when
LDL is less than 70 mg/dL has been found to improve
cardiovascular outcomes in CAD patients after ACS
[16], whether statin under-usage led to the poor out-
comes in DM patients in this study remains to be clari-
fied. In comparison with patients with DM only, patients
with hypertension alone and those with both DM and
hypertension used statins, high potency hypotensive
agents such as calcium channel blockers (CCB) and ARB
more frequently, which may have led to a better
prognosis.
No differences were found between groups regarding
lesion location and type of intervention such as balloon
angioplasty, bare metal stent deployment, or drug elut-
ing stent deployment. However, patients with both DM
and hypertension and those with DM alone had a
greater prevalence of dual vessel disease and triple vessel
disease; the SYNTAX scores were also higher than for
patients without DM and hypertension, and hyperten-
sion alone. Besides, based on optical coherence tomog-
raphy (OCT) study, the factors implicated with culprit
plaque rupture were different depending on clinical
presentations. Hypertension was the only predictor for
ST-segment elevation myocardial infarction (STEMI),
while advancing age, DM, and hyperlipidemia were the
predictors for non-ST segment elevation myocardial in-
farction (NSTEMI) and unstable angina (US) [17]. On
the other hand, in terms of the prevalence of multi-
vessel disease, number of diseased vessels and number
of treated lesions, no differences were found between
Fig. 1 a. Cumulative ratio of freedom from myocardial infarction among the four groups (P = 0.06). b. Cumulative ratio of freedom from all-death
among the four groups (P < 0.01). c. Cumulative ratio of freedom from cardiac death among the four groups (P < 0.01). d. Cumulative ratio of
freedom from repeated PCI among the four groups (P = 0.10)
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patients with DM alone and patients with hypertension
alone (P =NS). Compared with patients with hyperten-
sion alone, patients with both DM and hypertension had
a significantly higher risk of developing multi-vessel
disease (P = 0.04); however, compared to patients with
DM alone, patients with both DM and hypertension did
not have a significant risk of developing multi-vessel dis-
ease (P = 0.65). Comorbidity with DM in hypertension
patients might have the additional risk of multi-vessel
disease in comparison with patients with hypertension
alone. In terms of treated lesions, no differences were
found between patients with hypertension alone, and
patients with both DM and hypertension (1.5 ± 0.8 vs
1.6 ± 0.9, P = NS). However, patients with DM alone had
fewer treated lesions than patients with both DM and
hypertension (1.4 ± 0.8 vs 1.6 ± 0.9, P < 0.05). Although
the prevalence rate of multi-vessel disease of DM
patients was not different from patients with both DM
and hypertension, the DM alone patients received fewer
procedures providing aggressive revascularization.
Evidence-based medicine has shown that hypotensive
agents and statin provide target-organ protection [18–23].
In the present study, patients with DM alone had the
highest rates of MI, all-cause mortality and CV mortality
compared to the other groups. Similarly, when compared
with patients with DM and hypertension, patients with
DM alone had a significantly increased risk of MI, CV
death and all-death (P < 0.001, P < 0.002, and P < 0.006, re-
spectively). However, no significant differences were noted
in terms of MI, CV death and all-death between patients
with hypertension alone and patients with both DM and
hypertension (P = 0.50, P = 0.60, and P = 0.41, respect-
ively). This may be due to the fact that patients DM alone
had a higher rate of previous MI, less use of statins, and
less use of more potent hypotensive agents. Moreover, a
less aggressive invasive strategy may also have played an
important role. Hypertensive patients with or without
coexisting DM have a better prognosis because of greater
use of statins and potent hypotensive agents, and a more
aggressive invasive strategy.
Table 4 Significant predictors of outcome in the Cox proportion hazard model for MI, All-cause death, CV-death, Repeated PCI
Variable MI All-death CV-death Repeated PCI
HRa (95% C.I.) HRa (95% C.I.) HRa (95% C.I.) HRa (95% C.I.)
Group
Control 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM alone 2.15 (1.03–4.49)* 2.25 (1.19–4.26)* 1.90 (1.03–3.50)* 1.70 (1.19–2.44)**
HT alone 1.07 (0.49–2.33) 0.47 (0.19–1.14) 0.75 (0.37–1.53) 1.02 (0.75–1.38)
DM and HT 1.62 (0.79–3.33) 0.82 (0.39–1.72) 0.88 (0.45–1.71) 1.27 (0.92–1.75)
Age – 1.05 (1.02–1.07)** – –
CKD – 1.89 (1.06–3.36)* – –
Smoking – – – 1.48 (1.16–1.89)**
Previous MI 3.17 (1.80–5.57)** 2.87 (1.65–4.99)** 4.02 (2.38–6.8)** –
Stroke 2.05 (0.81–5.22) 4.12 (2.04–8.32)** 1.89 (0.95–3.76)* –
Diuretics – – 1.27 (0.74–2.17) –
Aspirin – 1.17 (0.55–2.47) –
P2Y12 inh – 2.87 (1.04–7.95)* –
BB – 0.47 (0.26–0.85)* 0.37 (0.22–0.64)** 1.56 (1.24–1.98)**
CCB – – – –
ACEI – – 0.33 (0.18–0.67)** –
ARB – – – –
Statin 0.43 (0.23–0.81)** 0.35 (0.17–0.70)** 0.32 (0.17–0.62)** –
Syntax score 1.03 (1.00–1.06)* 1.02 (0.99–1.04) 1.04 (1.01–1.06)** 1.00 (0.98–1.01)
DM alone diabetes alone, HT alone hypertension alone, DM and HT both DM and hypertension
CKD estimated glomerular filtration rate <60 ml/min, Previous MI history of previous myocardial infarction, P2Y12 inh P2Y12 receptor inhibitor of platelet, Beta B
beta-blockers, CCB calcium channel blocker, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, Syntax score Synergy between
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery score
*P < 0.05, **P < 0.01. aHR was adjusted for confounding
RMI Model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βMI + βstroke + βstatin + βsyntax
All-death model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βage + βCKD + βMI + βstroke + βbetab + βstatin + βsyntax
CV-death model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βMI + βstroke + βdiuretics + βbetab + βACEI + βstatin + βsyntax
Repeated-PCI model: y = βdummyDH1 + βdummyDH2 + βdummyDH3 + βMI + βsmoking + βbetab + βsyntax
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Study limitations
First, intensity of medical control such as tight blood
glucose control rate and BP control rate were not
surveyed in this study, adherence to drug therapy was
not evaluated in this study. Second, functional evalua-
tions of the atherosclerotic lesions, such as plaque com-
positions analysis and fraction flow reserve (FFR)
measurement, were not used, which may also have had
an impact on the index PCI. Third, the case number of
DM alone patients was smaller than for the other
groups, which may have affected the power of this study.
Fourth, this study is small and thus underpowered to
determine the effect of hypertension on CVD outcomes
after PCI, given smaller effect size and the need for a
longer duration of follow-up. Finally, since this is a
prospective cohort study, whether both aggressive
medical treatment and invasive strategy could improve
outcome in DM alone patients a remains to be clarified
by large randomized clinical trials.
Conclusions
Patients with DM alone have higher mortality than pa-
tients without DM and hypertension, with both DM and
hypertension, and with hypertension alone. Comorbid
hypertension appears not to increase risk in DM
patients, whereas comorbid DM appears to increase risk
in hypertensive patients.
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